X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs BIOCON LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA BIOCON LTD TORRENT PHARMA/
BIOCON LTD
 
P/E (TTM) x 37.7 93.8 40.2% View Chart
P/BV x 5.9 7.7 76.8% View Chart
Dividend Yield % 0.9 0.2 572.2%  

Financials

 TORRENT PHARMA   BIOCON LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
BIOCON LTD
Mar-17
TORRENT PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,162 152.1%   
Low Rs1,186483 245.7%   
Sales per share (Unadj.) Rs346.1194.6 177.9%  
Earnings per share (Unadj.) Rs55.234.4 160.4%  
Cash flow per share (Unadj.) Rs73.348.3 151.9%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %0.90.1 779.5%  
Book value per share (Unadj.) Rs257.1241.9 106.3%  
Shares outstanding (eoy) m169.22200.00 84.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.2 101.0%   
Avg P/E ratio x26.823.9 112.0%  
P/CF ratio (eoy) x20.117.0 118.3%  
Price / Book Value ratio x5.73.4 169.0%  
Dividend payout %25.42.9 873.1%   
Avg Mkt Cap Rs m249,887164,440 152.0%   
No. of employees `00011.89.2 127.6%   
Total wages/salary Rs m9,9347,470 133.0%   
Avg. sales/employee Rs Th4,971.54,213.9 118.0%   
Avg. wages/employee Rs Th843.2809.0 104.2%   
Avg. net profit/employee Rs Th792.4745.2 106.3%   
INCOME DATA
Net Sales Rs m58,56938,911 150.5%  
Other income Rs m2,2331,571 142.1%   
Total revenues Rs m60,80240,482 150.2%   
Gross profit Rs m13,7739,795 140.6%  
Depreciation Rs m3,0692,772 110.7%   
Interest Rs m2,056260 790.6%   
Profit before tax Rs m10,8818,334 130.6%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,616 95.6%   
Profit after tax Rs m9,3366,881 135.7%  
Gross profit margin %23.525.2 93.4%  
Effective tax rate %14.219.4 73.2%   
Net profit margin %15.917.7 90.1%  
BALANCE SHEET DATA
Current assets Rs m53,84140,477 133.0%   
Current liabilities Rs m31,61216,783 188.4%   
Net working cap to sales %38.060.9 62.3%  
Current ratio x1.72.4 70.6%  
Inventory Days Days9760 163.0%  
Debtors Days Days8483 101.1%  
Net fixed assets Rs m42,07945,073 93.4%   
Share capital Rs m8461,000 84.6%   
"Free" reserves Rs m42,65547,377 90.0%   
Net worth Rs m43,50148,377 89.9%   
Long term debt Rs m22,40821,082 106.3%   
Total assets Rs m101,25093,942 107.8%  
Interest coverage x6.333.1 19.0%   
Debt to equity ratio x0.50.4 118.2%  
Sales to assets ratio x0.60.4 139.7%   
Return on assets %11.37.6 148.0%  
Return on equity %21.514.2 150.9%  
Return on capital %19.612.6 155.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06612,988 154.5%   
Fx outflow Rs m5,3047,899 67.1%   
Net fx Rs m14,7625,089 290.1%   
CASH FLOW
From Operations Rs m10,1276,400 158.2%  
From Investments Rs m-7,869-4,985 157.9%  
From Financial Activity Rs m-1,918-1,775 108.1%  
Net Cashflow Rs m212-473 -44.7%  

Share Holding

Indian Promoters % 71.5 40.4 177.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.0 8.4 83.6%  
FIIs % 12.6 10.7 117.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.9 44.2%  
Shareholders   26,511 109,995 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

TORRENT PHARMA at 52 Week High; BSE 500 Index Down 0.3 %

Jun 19, 2018 | Updated on Jun 19, 2018

TORRENT PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,524. BSE 500 Index is down by 0.27% at 14,773. Within the BSE 500, TORRENT PHARMA (up 2.80%) and RELAXO FOOTWEARS (up 5.86%) are among the top gainers, while top losers are MANPASAND BEVERAGES and KRBL LIMITED.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 19, 2018 10:31 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS